Thamsborg G, Storm T L, Sykulski R, Brinch E, Nielsen H K, Sørensen O H
Department of Medicine, Sundby Hospital, Copenhagen, Denmark.
Calcif Tissue Int. 1991 May;48(5):302-7. doi: 10.1007/BF02556148.
Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass. They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray. The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was -0.4, -0.1, 0.0, and -0.1 AU per year, respectively. The rate of change in the bone mineral content of the lumbar spine in patients receiving 200 IU of SCT per day differed significantly from zero (P less than 0.01). Except for one patient, who experienced intolerable nausea, no systemic side effects were observed. Seven patients withdrew, two patients from nasal intolerance to the spray. These preliminary data suggest that SCT given by the nasal route has a positive and dose-dependent effect on spinal bone mass, but affects forearm bone mass only minimally.
40名有过Colles骨折的绝经后女性参与了一项为期1年的研究，以确定鼻用鲑鱼降钙素（SCT）对骨量的剂量效应关系。她们被随机分为接受安慰剂组，以及每天分别给予50、100或200国际单位SCT的鼻喷雾剂组。腰椎骨矿物质含量的年变化率分别为0.7、0.2、1.1和2.0 gHA，前臂骨矿物质含量的年变化率分别为-0.4、-0.1、0.0和-0.1 AU。每天接受200国际单位SCT的患者腰椎骨矿物质含量的变化率与零有显著差异（P小于0.01）。除一名患者出现无法耐受的恶心外，未观察到全身性副作用。7名患者退出，两名患者因对喷雾剂不耐受。这些初步数据表明，经鼻给予SCT对脊柱骨量有积极的剂量依赖性影响，但对前臂骨量影响极小。
